nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—HMGA1—muscle cancer	0.105	0.28	CbGpPWpGaD
Plerixafor—CXCR4—embryo—muscle cancer	0.0711	0.169	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF3—muscle cancer	0.0708	0.19	CbGpPWpGaD
Plerixafor—CXCR4—smooth muscle tissue—muscle cancer	0.0559	0.133	CbGeAlD
Plerixafor—CXCR4—renal system—muscle cancer	0.0538	0.128	CbGeAlD
Plerixafor—CXCR4—cardiac atrium—muscle cancer	0.0482	0.114	CbGeAlD
Plerixafor—CXCR4—tendon—muscle cancer	0.042	0.0997	CbGeAlD
Plerixafor—CXCR4—bone marrow—muscle cancer	0.0407	0.0965	CbGeAlD
Plerixafor—CXCR4—vagina—muscle cancer	0.039	0.0925	CbGeAlD
Plerixafor—CXCR4—head—muscle cancer	0.036	0.0854	CbGeAlD
Plerixafor—CXCR4—testis—muscle cancer	0.0348	0.0825	CbGeAlD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF2—muscle cancer	0.0259	0.0695	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—muscle cancer	0.0199	0.0532	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KIT—muscle cancer	0.0182	0.0487	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—HMGA1—muscle cancer	0.017	0.0454	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—FOXO1—muscle cancer	0.0165	0.0442	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—HMGA1—muscle cancer	0.0117	0.0314	CbGpPWpGaD
Plerixafor—Induration—Etoposide—muscle cancer	0.00975	0.0476	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CNR1—muscle cancer	0.00964	0.0258	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.00913	0.0245	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00895	0.024	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00767	0.0205	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—PTCH1—muscle cancer	0.00692	0.0185	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CNR1—muscle cancer	0.00584	0.0156	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Vincristine—muscle cancer	0.00545	0.0266	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—KIDINS220—muscle cancer	0.00533	0.0143	CbGpPWpGaD
Plerixafor—Inflammation—Etoposide—muscle cancer	0.0045	0.0219	CcSEcCtD
Plerixafor—Swelling—Etoposide—muscle cancer	0.00359	0.0175	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PTCH1—muscle cancer	0.00355	0.00951	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CNR1—muscle cancer	0.0033	0.00884	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ENO2—muscle cancer	0.00316	0.00846	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CNR1—muscle cancer	0.003	0.00802	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HMGA1—muscle cancer	0.00287	0.00769	CbGpPWpGaD
Plerixafor—Inflammation—Methotrexate—muscle cancer	0.00269	0.0131	CcSEcCtD
Plerixafor—Connective tissue disorder—Vincristine—muscle cancer	0.00266	0.013	CcSEcCtD
Plerixafor—Erythema—Dactinomycin—muscle cancer	0.00263	0.0129	CcSEcCtD
Plerixafor—CXCR4—Disease—FOXO4—muscle cancer	0.00257	0.0069	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Dactinomycin—muscle cancer	0.00244	0.0119	CcSEcCtD
Plerixafor—Malaise—Dactinomycin—muscle cancer	0.00238	0.0116	CcSEcCtD
Plerixafor—Mental disorder—Vincristine—muscle cancer	0.00237	0.0116	CcSEcCtD
Plerixafor—Inflammation—Doxorubicin—muscle cancer	0.00233	0.0114	CcSEcCtD
Plerixafor—Musculoskeletal pain—Doxorubicin—muscle cancer	0.00229	0.0112	CcSEcCtD
Plerixafor—Injection site reaction—Doxorubicin—muscle cancer	0.00225	0.011	CcSEcCtD
Plerixafor—Discomfort—Dactinomycin—muscle cancer	0.00222	0.0108	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTCH1—muscle cancer	0.0021	0.00562	CbGpPWpGaD
Plerixafor—Immune system disorder—Etoposide—muscle cancer	0.00198	0.00965	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00196	0.00956	CcSEcCtD
Plerixafor—Anaphylactic shock—Vincristine—muscle cancer	0.00192	0.00937	CcSEcCtD
Plerixafor—CXCR4—Disease—FOXO1—muscle cancer	0.0019	0.00509	CbGpPWpGaD
Plerixafor—Nervous system disorder—Vincristine—muscle cancer	0.00188	0.00919	CcSEcCtD
Plerixafor—Hyperhidrosis—Vincristine—muscle cancer	0.00186	0.00906	CcSEcCtD
Plerixafor—Fatigue—Dactinomycin—muscle cancer	0.00185	0.00904	CcSEcCtD
Plerixafor—Pain—Dactinomycin—muscle cancer	0.00184	0.00897	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FOXO4—muscle cancer	0.0018	0.00483	CbGpPWpGaD
Plerixafor—Feeling abnormal—Dactinomycin—muscle cancer	0.00177	0.00864	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CNR1—muscle cancer	0.00177	0.00474	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Etoposide—muscle cancer	0.00177	0.00863	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00176	0.00858	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00175	0.00854	CcSEcCtD
Plerixafor—Insomnia—Vincristine—muscle cancer	0.00174	0.00848	CcSEcCtD
Plerixafor—Paraesthesia—Vincristine—muscle cancer	0.00172	0.00842	CcSEcCtD
Plerixafor—Malaise—Etoposide—muscle cancer	0.00172	0.00839	CcSEcCtD
Plerixafor—Abdominal pain—Dactinomycin—muscle cancer	0.0017	0.00829	CcSEcCtD
Plerixafor—Loss of consciousness—Etoposide—muscle cancer	0.00168	0.00818	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vincristine—muscle cancer	0.00166	0.00809	CcSEcCtD
Plerixafor—Fatigue—Vincristine—muscle cancer	0.00166	0.00808	CcSEcCtD
Plerixafor—Pain—Vincristine—muscle cancer	0.00164	0.00802	CcSEcCtD
Plerixafor—Constipation—Vincristine—muscle cancer	0.00164	0.00802	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00161	0.00787	CcSEcCtD
Plerixafor—Discomfort—Etoposide—muscle cancer	0.0016	0.00783	CcSEcCtD
Plerixafor—Hypersensitivity—Dactinomycin—muscle cancer	0.00158	0.00773	CcSEcCtD
Plerixafor—Abdominal discomfort—Methotrexate—muscle cancer	0.00157	0.00767	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vincristine—muscle cancer	0.00157	0.00766	CcSEcCtD
Plerixafor—Anaphylactic shock—Etoposide—muscle cancer	0.00156	0.00759	CcSEcCtD
Plerixafor—Asthenia—Dactinomycin—muscle cancer	0.00154	0.00753	CcSEcCtD
Plerixafor—Abdominal pain—Vincristine—muscle cancer	0.00152	0.00741	CcSEcCtD
Plerixafor—Skin disorder—Etoposide—muscle cancer	0.00151	0.00737	CcSEcCtD
Plerixafor—Hyperhidrosis—Etoposide—muscle cancer	0.0015	0.00734	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—muscle cancer	0.0015	0.00732	CcSEcCtD
Plerixafor—Diarrhoea—Dactinomycin—muscle cancer	0.00147	0.00718	CcSEcCtD
Plerixafor—CXCR4—Disease—KIT—muscle cancer	0.00145	0.00388	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF2—muscle cancer	0.00145	0.00388	CbGpPWpGaD
Plerixafor—Abdominal distension—Doxorubicin—muscle cancer	0.00143	0.00697	CcSEcCtD
Plerixafor—Hypersensitivity—Vincristine—muscle cancer	0.00142	0.00691	CcSEcCtD
Plerixafor—Paraesthesia—Etoposide—muscle cancer	0.0014	0.00682	CcSEcCtD
Plerixafor—Dyspnoea—Etoposide—muscle cancer	0.00139	0.00677	CcSEcCtD
Plerixafor—Asthenia—Vincristine—muscle cancer	0.00138	0.00672	CcSEcCtD
Plerixafor—Vomiting—Dactinomycin—muscle cancer	0.00137	0.00667	CcSEcCtD
Plerixafor—Rash—Dactinomycin—muscle cancer	0.00136	0.00661	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Etoposide—muscle cancer	0.00134	0.00655	CcSEcCtD
Plerixafor—Fatigue—Etoposide—muscle cancer	0.00134	0.00655	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FOXO1—muscle cancer	0.00133	0.00357	CbGpPWpGaD
Plerixafor—Pain—Etoposide—muscle cancer	0.00133	0.00649	CcSEcCtD
Plerixafor—Constipation—Etoposide—muscle cancer	0.00133	0.00649	CcSEcCtD
Plerixafor—Haemoglobin—Methotrexate—muscle cancer	0.00132	0.00643	CcSEcCtD
Plerixafor—Diarrhoea—Vincristine—muscle cancer	0.00131	0.00641	CcSEcCtD
Plerixafor—Haemorrhage—Methotrexate—muscle cancer	0.00131	0.0064	CcSEcCtD
Plerixafor—Feeling abnormal—Etoposide—muscle cancer	0.00128	0.00626	CcSEcCtD
Plerixafor—Nausea—Dactinomycin—muscle cancer	0.00128	0.00623	CcSEcCtD
Plerixafor—Gastrointestinal pain—Etoposide—muscle cancer	0.00127	0.00621	CcSEcCtD
Plerixafor—Dizziness—Vincristine—muscle cancer	0.00127	0.0062	CcSEcCtD
Plerixafor—Urticaria—Etoposide—muscle cancer	0.00124	0.00603	CcSEcCtD
Plerixafor—Abdominal pain—Etoposide—muscle cancer	0.00123	0.006	CcSEcCtD
Plerixafor—Vomiting—Vincristine—muscle cancer	0.00122	0.00596	CcSEcCtD
Plerixafor—Rash—Vincristine—muscle cancer	0.00121	0.00591	CcSEcCtD
Plerixafor—Dermatitis—Vincristine—muscle cancer	0.00121	0.0059	CcSEcCtD
Plerixafor—Headache—Vincristine—muscle cancer	0.0012	0.00587	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—muscle cancer	0.00118	0.00578	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—muscle cancer	0.00115	0.00561	CcSEcCtD
Plerixafor—Hypersensitivity—Etoposide—muscle cancer	0.00115	0.00559	CcSEcCtD
Plerixafor—Erythema—Methotrexate—muscle cancer	0.00114	0.00557	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—muscle cancer	0.00114	0.00557	CcSEcCtD
Plerixafor—CXCR4—Disease—MDM2—muscle cancer	0.00114	0.00306	CbGpPWpGaD
Plerixafor—Nausea—Vincristine—muscle cancer	0.00114	0.00557	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—muscle cancer	0.00114	0.00554	CcSEcCtD
Plerixafor—Asthenia—Etoposide—muscle cancer	0.00112	0.00545	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—muscle cancer	0.00112	0.00545	CcSEcCtD
Plerixafor—Pruritus—Etoposide—muscle cancer	0.0011	0.00537	CcSEcCtD
Plerixafor—CXCR4—Disease—PTGS2—muscle cancer	0.0011	0.00295	CbGpPWpGaD
Plerixafor—Diarrhoea—Etoposide—muscle cancer	0.00106	0.00519	CcSEcCtD
Plerixafor—Ill-defined disorder—Methotrexate—muscle cancer	0.00106	0.00517	CcSEcCtD
Plerixafor—Malaise—Methotrexate—muscle cancer	0.00103	0.00503	CcSEcCtD
Plerixafor—Dizziness—Etoposide—muscle cancer	0.00103	0.00502	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—muscle cancer	0.00103	0.00501	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—KIT—muscle cancer	0.00101	0.00272	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—muscle cancer	0.000995	0.00486	CcSEcCtD
Plerixafor—Vomiting—Etoposide—muscle cancer	0.000989	0.00483	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—muscle cancer	0.000989	0.00483	CcSEcCtD
Plerixafor—Rash—Etoposide—muscle cancer	0.000981	0.00479	CcSEcCtD
Plerixafor—Dermatitis—Etoposide—muscle cancer	0.00098	0.00478	CcSEcCtD
Plerixafor—Headache—Etoposide—muscle cancer	0.000975	0.00476	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—muscle cancer	0.000974	0.00475	CcSEcCtD
Plerixafor—Arthralgia—Methotrexate—muscle cancer	0.000972	0.00474	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000966	0.00471	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—muscle cancer	0.000961	0.00469	CcSEcCtD
Plerixafor—Anaphylactic shock—Methotrexate—muscle cancer	0.000932	0.00455	CcSEcCtD
Plerixafor—Nausea—Etoposide—muscle cancer	0.000924	0.00451	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—muscle cancer	0.000917	0.00448	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—muscle cancer	0.000914	0.00446	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—muscle cancer	0.000905	0.00442	CcSEcCtD
Plerixafor—Hyperhidrosis—Methotrexate—muscle cancer	0.000901	0.0044	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—muscle cancer	0.000892	0.00435	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—muscle cancer	0.000887	0.00433	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—muscle cancer	0.000869	0.00424	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000849	0.00414	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—muscle cancer	0.000843	0.00411	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—muscle cancer	0.000842	0.00411	CcSEcCtD
Plerixafor—Paraesthesia—Methotrexate—muscle cancer	0.000837	0.00408	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000836	0.00408	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—muscle cancer	0.000832	0.00406	CcSEcCtD
Plerixafor—Dyspnoea—Methotrexate—muscle cancer	0.000831	0.00405	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—muscle cancer	0.000823	0.00402	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—muscle cancer	0.00082	0.004	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—muscle cancer	0.000807	0.00394	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000805	0.00393	CcSEcCtD
Plerixafor—Fatigue—Methotrexate—muscle cancer	0.000804	0.00392	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MDM2—muscle cancer	0.000799	0.00214	CbGpPWpGaD
Plerixafor—Pain—Methotrexate—muscle cancer	0.000797	0.00389	CcSEcCtD
Plerixafor—Shock—Doxorubicin—muscle cancer	0.000794	0.00387	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—muscle cancer	0.000791	0.00386	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—muscle cancer	0.000784	0.00383	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—muscle cancer	0.00078	0.00381	CcSEcCtD
Plerixafor—Feeling abnormal—Methotrexate—muscle cancer	0.000768	0.00375	CcSEcCtD
Plerixafor—Gastrointestinal pain—Methotrexate—muscle cancer	0.000762	0.00372	CcSEcCtD
Plerixafor—Urticaria—Methotrexate—muscle cancer	0.00074	0.00361	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—muscle cancer	0.000737	0.0036	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000735	0.00359	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—muscle cancer	0.00073	0.00356	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—muscle cancer	0.000725	0.00354	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—muscle cancer	0.00072	0.00351	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—muscle cancer	0.00071	0.00347	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000697	0.0034	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—muscle cancer	0.000696	0.0034	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—muscle cancer	0.00069	0.00337	CcSEcCtD
Plerixafor—Pain—Doxorubicin—muscle cancer	0.00069	0.00337	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—muscle cancer	0.000687	0.00335	CcSEcCtD
Plerixafor—Asthenia—Methotrexate—muscle cancer	0.000669	0.00326	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—muscle cancer	0.000665	0.00325	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00066	0.00322	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—muscle cancer	0.000659	0.00322	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—muscle cancer	0.000641	0.00313	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—muscle cancer	0.000638	0.00311	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—muscle cancer	0.000638	0.00311	CcSEcCtD
Plerixafor—Dizziness—Methotrexate—muscle cancer	0.000616	0.00301	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—muscle cancer	0.000607	0.00163	CbGpPWpGaD
Plerixafor—Hypersensitivity—Doxorubicin—muscle cancer	0.000595	0.0029	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—muscle cancer	0.000593	0.00289	CcSEcCtD
Plerixafor—Rash—Methotrexate—muscle cancer	0.000588	0.00287	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—muscle cancer	0.000587	0.00286	CcSEcCtD
Plerixafor—Headache—Methotrexate—muscle cancer	0.000584	0.00285	CcSEcCtD
Plerixafor—Asthenia—Doxorubicin—muscle cancer	0.000579	0.00283	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—muscle cancer	0.000571	0.00279	CcSEcCtD
Plerixafor—Nausea—Methotrexate—muscle cancer	0.000554	0.0027	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—muscle cancer	0.000552	0.00269	CcSEcCtD
Plerixafor—Dizziness—Doxorubicin—muscle cancer	0.000534	0.0026	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—muscle cancer	0.000513	0.0025	CcSEcCtD
Plerixafor—Rash—Doxorubicin—muscle cancer	0.000509	0.00248	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—muscle cancer	0.000508	0.00248	CcSEcCtD
Plerixafor—Headache—Doxorubicin—muscle cancer	0.000506	0.00247	CcSEcCtD
Plerixafor—Nausea—Doxorubicin—muscle cancer	0.000479	0.00234	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TP53—muscle cancer	0.000458	0.00123	CbGpPWpGaD
